Acute myeloid leukemia with minimal differentiation

disease
On this page

Also known as acute myeloblastic leukaemia with minimal differentiationacute myeloblastic leukemia with minimal differentiationacute myeloblastic leukemia, minimally differentiatedacute myelocytic leukaemia with minimal differentiationacute myelocytic leukemia with minimal differentiationacute myelogenous leukaemia with minimal differentiationacute myelogenous leukemia with minimal differentiationacute myeloid leukaemia with minimal differentiation (MO)acute myeloid leukemia with minimal differentiation (MO)acute myeloid leukemia, minimally differentiatedAML M0AML with minimal differentiationAMLMDM0 acute granulocytic leukaemiaM0 acute granulocytic leukaemia with minimal differentiationM0 acute granulocytic leukemiaM0 acute granulocytic leukemia with minimal differentiationM0 acute myeloblastic leukaemiaM0 acute myeloblastic leukemia

Summary

Acute myeloid leukemia with minimal differentiation (MONDO:0005223) is a cancer. A subtype of acute myeloid leukemia by FAB classification — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Classification: Cancer
  • Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

TypeClassValueGeographyValidation
Annual incidence<1 / 1 000 0000.01EuropeValidated

Identifiers

Disease identifiers

FieldValue
Canonical nameacute myeloid leukemia with minimal differentiation
Mondo IDMONDO:0005223
EFOEFO:0003026
Orphanet98832
DOIDDOID:0081085
ICD-111468530237
NCITC8460
UMLSC0522631
MedGen101100
GARD0019588
Is cancer (heuristic)yes

Also known as: acute myeloblastic leukaemia with minimal differentiation · acute myeloblastic leukemia with minimal differentiation · acute myeloblastic leukemia, minimally differentiated · acute myelocytic leukaemia with minimal differentiation · acute myelocytic leukemia with minimal differentiation · acute myelogenous leukaemia with minimal differentiation · acute myelogenous leukemia with minimal differentiation · acute myeloid leukaemia with minimal differentiation (MO) · acute myeloid leukemia with minimal differentiation · acute myeloid leukemia with minimal differentiation (MO) · acute myeloid leukemia, minimally differentiated · AML M0 · AML with minimal differentiation · AMLMD · M0 acute granulocytic leukaemia · M0 acute granulocytic leukaemia with minimal differentiation · M0 acute granulocytic leukemia · M0 acute granulocytic leukemia with minimal differentiation · M0 acute myeloblastic leukaemia · M0 acute myeloblastic leukemia (+12 more)

Data availability: 3 cell lines.

Disease family

This is a subtype of acute myeloid leukemia by FAB classification. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmhematopoietic and lymphoid system neoplasmhematopoietic and lymphoid cell neoplasmleukemiamyeloid leukemiaacute myeloid leukemiaacute myeloid leukemia by FAB classificationacute myeloid leukemia with minimal differentiation

Related subtypes (8): acute myeloblastic leukemia without maturation, myeloid sarcoma, acute erythroid leukemia, acute myelomonocytic leukemia M4, acute megakaryoblastic leukemia, acute panmyelosis with myelofibrosis, acute basophilic leukemia, acute myeloblastic leukemia with maturation

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.